2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99957
    Zeluvalimab
    		Inhibitor
    Zeluvalimab (AMG-404) is a monoclonal antibody targeting the PD-1 receptor that can be used for the research of cancer.
    Zeluvalimab
  • HY-P990701
    Lomvastomig
    Lomvastomig is an anti-PDCD1/HAVCR2 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Lomvastomig
  • HY-P99938
    Pucotenlimab
    Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor.
    Pucotenlimab
  • HY-P99963
    Sudubrilimab
    		Inhibitor
    Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment.
    Sudubrilimab
  • HY-129172
    PD-1/PD-L1-IN 5 TFA
    		Inhibitor
    PD-1/PD-L1-IN 5 TFA is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM.
    PD-1/PD-L1-IN 5 TFA
  • HY-P990072
    Lipustobart
    		Inhibitor
    Lipustobart is an IgG4-kappa, anti-PDCD1 (programmed cell death 1, PD1, PD-1, CD279) humanized monoclonal antibody. Lipustobart shows immunostimulant and antineoplastic activity.
    Lipustobart
  • HY-P2474
    Human PD-L1 inhibitor I
    		98.93%
    Human PD-L1 inhibitor I is a hPD-1 peptide ligand, with a KD of 3.39 μM. Human PD-L1 inhibitor I may disturb the binding of hPD-L1 to hPD-1.
    Human PD-L1 inhibitor I
  • HY-P2478
    Human PD-L1 inhibitor V
    		Inhibitor 99.04%
    Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1.
    Human PD-L1 inhibitor V
  • HY-168491
    Enpp-1-IN-25
    Enpp-1-IN-25 (Compound 30) is an ENPP1 inhibitor with an IC50 of 8.05 nM and low oral bioavailability. Enpp-1-IN-25 can effectively activate the intracellular STING pathway by inhibiting cGAMP degradation. Enpp-1-IN-25 can enhance immune cell infiltration in the tumor microenvironment and type I interferon responses, and potentiate the antitumor efficacy of the anti-PD-L1 antibody. Enpp-1-IN-25 can be used in the research of cancer immunotherapy.
    Enpp-1-IN-25
  • HY-N0596R
    Panaxadiol (Standard)
    		Inhibitor
    Panaxadiol (Standard) is the analytical standard of Panaxadiol. This product is intended for research and analytical applications. Panaxadiol (20(R)-Panaxadiol) is an orally active HIF-1α/STAT3 inhibitor. Panaxadiol can suppress HIF-1α and STAT3 then lead to downregulation of programmed cell death-ligand 1 (PD-L1) expression. Panaxadiol shows anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities.
    Panaxadiol (Standard)
  • HY-161748
    PD-1/PD-L1-IN-46
    		Antagonist
    PD-1/PD-L1-IN-46 (compound (R)-C27 ) is an PD-1/PD-L1 antagonist with IC50 value of 18.66 nM.
    PD-1/PD-L1-IN-46
  • HY-161818
    LLW-018
    		Inhibitor
    LLW-018 is a potent PD-1/PD-L1 inhibitor with an IC50 value of 2.61 nM. LLW-018 can interrupt PD-1/PD-L1 interaction with an IC50 value of 0.88 μM by cell-based PD-1/PD-L1 blockade bioassays. LLW-018 has the potential for immunotherapy research.
    LLW-018
  • HY-130625
    PD-1/PD-L1-IN 6
    		Inhibitor
    PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a T cell-tumor co-culture model.
    PD-1/PD-L1-IN 6
  • HY-P990486
    Anti-PDCD1/PD-1/CD279 Antibody
    		Inhibitor
    Anti-PDCD1/PD-1/CD279 Antibody is a CHO-expressed humanized antibody that targets PDCD1/PD-1/CD279. Anti-PDCD1/PD-1/CD279 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-PDCD1/PD-1/CD279 Antibody can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Anti-PDCD1/PD-1/CD279 Antibody
  • HY-P990690
    Volrustomig
    Volrustomig is an anti-CTLA4/PDCD1 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Volrustomig
  • HY-155740
    PD-1/PD-L1-IN-32
    		Inhibitor
    PD-1/PD-L1-IN-32 (compound A56) is a potent PD-1/PD-L1 inhibitor (IC50=2.4 nM), with anticancer activity. PD-1/PD-L1-IN-32 significantly inhibits tumor growth in hPD-L1 MC38 humanized mouse model, without obvious toxicity against mouse normal ability.
    PD-1/PD-L1-IN-32
  • HY-151066
    BMS-1233
    		Inhibitor
    BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model.
    BMS-1233
  • HY-P4072
    (D)-PPA 1
    		Inhibitor
    (D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.
    (D)-PPA 1
  • HY-169365
    2-Methylbiphenyl-oxadiazole-NH-Ph-CHO
    		Ligand
    2-Methylbiphenyl-oxadiazole-NH-Ph-CHO is the PD-L1 ligand part of AUTAC PD-L1 degrader-3 (HY-169363). 2-Methylbiphenyl-oxadiazole-NH-Ph-CHO can be utilized in AUTAC synthesis.
    2-Methylbiphenyl-oxadiazole-NH-Ph-CHO
  • HY-P990716
    Sabestomig
    Sabestomig is an anti-PDCD1/HAVCR2 Ig(G1-κ G1-λ2) monoclonal antibody.
    Sabestomig
Cat. No. Product Name / Synonyms Application Reactivity